ERSO - System Oncology
Alternative Names: Unfolded protein response therapeutic - System oncology/Bayer; UPR therapeutic - System Oncology/BayerLatest Information Update: 28 Oct 2024
Price :
$50 *
At a glance
- Originator University of Illinois
- Developer Bayer; Systems Oncology
- Class Antineoplastics; Small molecules
- Mechanism of Action Apoptosis stimulants; Estrogen receptor alpha agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Breast cancer
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for preclinical development in Breast-cancer in Germany (PO)
- 28 Oct 2024 No recent reports of development identified for preclinical development in Breast-cancer in USA (PO)
- 15 Sep 2020 System Oncology in-licenses intellectual property from University of Illinois prior to September 2020